A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy

Prenatal Diagnosis

Volumn 30, Issue 10, 2010, Pages 937-940

  Spencer, K ^a   Cowans, N J ^a   Spencer, C E ^a   Achillea, N ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Free human chorionic gonadotrophin; Nuchal translucency; Pregnancy associated plasma protein A; Prenatal screening; Trisomy 21

Indexed keywords

BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ANEUPLOIDY; ARTICLE; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL DIABETES MELLITUS; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; TRISOMY 21;

ADULT; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DIABETES MELLITUS, TYPE 1; DOWN SYNDROME; FEMALE; GENETIC COUNSELING; HUMANS; MASS SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROSPECTIVE STUDIES; ULTRASONOGRAPHY, PRENATAL;

EID: 77957333750     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2589     Document Type: Article

References (17)

1. Bartha JL, Wood J, Kyle PM, Soothill PW. 2003. The effect of metabolic control on fetal nuchal translucency in women with insulin-dependent diabetes: a preliminary study. Ultrasond Obstet Gynecol 21: 451-454.
2. CEMACH. 2005. Confidential Enquiry into Maternal and Child Health: Pregnancy in Women with Type 1 and Type 2 Diabetes in 2002-03. England, Wales and Northern Ireland. CEMACH: London.
3. Huttly W, Rudnicka A, Wald NJ. 2004. Second trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 24: 804-807.
4. Kagan KO, Frisova V, Nicolaides KH, Spencer K. 2007. Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13 + 6 weeks of gestation. Prenat Diagn 27: 849-853. (Pubitemid 47425405)
5. Nice Guidelines. 2008. Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. RCOG: London.
6. Nix B, Wright D, Baker A. 2007. The impact of bias in MoM values on patient risk and screening performance for Down syndrome. Prenat Diagn 27: 840-845.
7. Ong CYT, Liao A, Spencer K, Munim S, Nicolaides KH. 2000. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. Br J Obstet Gynaecol 107: 1265-1270.
8. Pedersen JF, Sorensen S, Molsted-Pedersen L. 1998. Serum levels of human placental lactogen, pregnancy associated plasma protein A and endometrial secretory protein PP14 in first trimester of diabetic pregnancy. Acta Obstet Gynecol Scand 77: 155-158.
9. Pellitero S, Reverter JL, Pizarro E, et al. 2007. Pregnancy associated plasma protein-A levels are related to glycemic control but not lipid profile or hemostatic parameters in Type 2 diabetes. Diabetes Care 30: 3083-3085.
10. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. 1999. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynecol 13: 167-170. (Pubitemid 29176889)
11. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
12. Spencer K, Ong CY, Liao AW, Nicolaides KH. 2000. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 20: 491-494.
13. Spencer K, Bindra R, Nicolaides KH. 2003a. Maternal weight correction of maternal serum PAPP-A and free beta hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 23: 851-855.
14. Spencer K, Bindra R, Nix ABJ, Heath V, Nicolaides KH. 2003b. Delta NT or NT MoM: which is the most appropriate for calculating accurate patient specific risks for trisomy 21 in the first trimester?. Ultrasound Obstet Gynecol 22: 142-148. (Pubitemid 36976380)
15. Spencer K, Bindra R, Cacho AM, Nicolaides KH. 2004. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 24: 169-171.
16. Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH. 2005a. The influence of maternal insulin dependent diabetes on fetal nuchal translucency thickness and first trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 25: 927-929.
17. Spencer K, Heath V, El-Sheikhah A, Ong CYT, Nicolaides KH. 2005b. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn 25: 365-369.